The strong DAYBUE growth and raised guidance confirm commercial momentum, but the decline in net income and elevated SG&A warrant monitoring. The upcoming Phase 2 readouts for ACP-211 and remlifanserin in LBDP in 2027 are key pipeline catalysts.
Drugs in focus
ACAD drug pipeline →DAYBUE
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed in the US (since March 2023) and EU (since August 2026). Japan regulatory filing planned for 2027 with potential launch in 2028.
- Next catalyst
- None dated
What to watchDAYBUE is already approved and generating strong commercial revenue. The next catalyst for this specific drug is the planned Japan regulatory filing in 2027, which could support a 2028 launch, but no hard date is set. Watch quarterly DAYBUE sales growth trajectory and European launch uptake (Germany launched October 2026) as the key near-term value drivers for ACAD stock.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $21.24entry
- T+1 · 11d ago −0.05%α −0.36% · $21.23
- T+5 · 5d ago −14.60%α −17.89% · $18.14
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Acadia Pharmaceuticals reported Q3 2026 GAAP total revenues of $342M, up 22% YoY on a non-GAAP adjusted basis, and GAAP diluted EPS of $0.31, which beat the $0.18 consensus. DAYBUE net sales grew 39% YoY to $140M, driven by DAYBUE STIX uptake. The company raised its 2026 DAYBUE guidance to $505-$520M and narrowed total revenue guidance to $1.265-$1.295B, while net income declined to $54M from $72M in the prior year due to higher SG&A and a large income tax expense.
Key Financial Metrics
Key Facts
- Q3 2026 GAAP total revenues of $342M, up 22% YoY on a non-GAAP adjusted basis
- GAAP diluted EPS of $0.31, above consensus estimate of $0.18
- DAYBUE net sales of $140M, up 39% YoY
- NUPLAZID net sales of $202M, up 12% YoY on a non-GAAP adjusted basis
- 2026 DAYBUE guidance raised to $505-$520M from $480-$510M
- Total revenue guidance narrowed to $1.265-$1.295B from $1.24-$1.30B
- Net income of $54M vs $72M in Q3 2025, impacted by $26.9M income tax expense vs a $27.2M benefit in the prior year
- Cash and investments of $976M at September 30, 2026, up from $820M at December 31, 2025
- Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis showed consistent efficacy trends, supporting Phase 3 development
- FDA Fast Track designation received for remlifanserin in Lewy body dementia psychosis
Financial Impact
Q3 revenue of $342M beat consensus of $332.6M by ~2.8%; EPS of $0.31 beat consensus of $0.18 by 72.2%; DAYBUE guidance raised by $25M at the midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| NUPLAZID | $202.2M | +12.0% |
| DAYBUE | $140.1M | +39.0% |
Risk Factors
- Net income declined YoY due to higher SG&A and a large income tax expense swing
- SG&A expenses rose to $159M from $133M, outpacing revenue growth
- Dependence on continued DAYBUE STIX uptake and European DAYBU launch success
- Pipeline risk: Phase 2 readouts in 2027 may not meet expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447276 |
| Document: acad-20261104.htm | 0001193125-26-447276 |
| Document: 0001193125-26-447276-index-headers.html | 0001193125-26-447276 |
| Document: 0001193125-26-447276-index.html | 0001193125-26-447276 |
| Document: 0001193125-26-447276.txt | 0001193125-26-447276 |
| 8-K Data (Synthetic) | 0001193125-26-447276 |
Track record
14 reports on ACAD
1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +5.01% at T+20 after the May 6, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
- Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $21.24 Now $18.67 −12.10% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
- Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
- Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers